Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A Hochhaus - Leukemia, 2004 - nature.com
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
被引用次数：459 相关文章

[引用][C] Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A HOCHHAUS - Leukemia, 2004 - cir.nii.ac.jp
Imatinib therapy in chronic myelogenous leukemia : strategies to avoid and overcome
resistance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.

A Hochhaus, P La Rosée - Leukemia (08876924), 2004 - search.ebscohost.com
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A Hochhaus, P La Rosée - Leukemia, 2004 - pubmed.ncbi.nlm.nih.gov
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A Hochhaus, P La Rosee - Leukemia, 2004 - go.gale.com
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

[引用][C] Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A HOCHHAUS, P LA ROSEE - Leukemia, 2004 - pascal-francis.inist.fr
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome
resistance CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.

A Hochhaus, P La Rosée - Leukemia, 2004 - europepmc.org
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

[引用][C] Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A Hochhaus, P La Rosée - Leukemia, 2004 - cir.nii.ac.jp
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome
resistance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

[引用][C] Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

A Hochhaus, P La Rosée - Leukemia, 2004 - Nature Publishing Group